Highlights

So, the results [of POLARIX] are pretty good, I won’t overstate them. The benefit is significant, not huge, but significant, and the increased toxicity – I guess maybe you will talk about it separately, but the increased toxicity is moderate. It’s significant but not huge. So, the results are pretty good… I think ultimately academic practices like ours, if this gets approved in July, by August we’d be using this in almost 50% of patients, and we’d have a quick penetration because academics are supposed to be leaders or whatever. I think the community would get near to that, it would take longer, the penetration could be slower, but I could easily see the community using this regimen in 40% of DLBCL patients.

For transplant-eligible patients, we unfortunately try to walk them down the path towards autologous stem cell transplant, I say unfortunately because I think it was a good therapy in 1995 when it was invented or when it became standard here, but it is not a good therapy now, it is resting on its laurels from its success 26 years ago in the PARMA trial. So, we unfortunately walk people down that standard of care, giving them platinum chemotherapy, and if they get a great response, for sure take them to stem cell transplant, but that is a minority of patients that walk all the way down that path.

For the transplant-ineligible patients, we mostly just treat them as though they were third-line patients from the transplant-eligible group. So, I can give you a long list of things we give them, and I can talk about how we prioritize those things